Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Pruritus Therapeutics Market, by Disease Type
1.4.2 Europe Pruritus Therapeutics Market, by Product
1.4.3 Europe Pruritus Therapeutics Market, by Distribution Channel
1.4.4 Europe Pruritus Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Force Analysis
Chapter 4. Europe Pruritus Therapeutics Market by Disease Type
4.1 Europe Atopic Dermatitis Market by Country
4.2 Europe Allergic Contact Dermatitis Market by Country
4.3 Europe Urticaria Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Pruritus Therapeutics Market by Product
5.1 Europe Corticosteroids Market by Country
5.2 Europe Antihistamines Market by Country
5.3 Europe Local Anesthetics Market by Country
5.4 Europe Counterirritants Market by Country
5.5 Europe Immunosuppressant Market by Country
5.6 Europe Calcineurin Inhibitors Market by Country
5.7 Europe Others Market by Country
Chapter 6. Europe Pruritus Therapeutics Market by Distribution Channel
6.1 Europe Drug Stores & Retail Pharmacies Market by Country
6.2 Europe Hospital Pharmacies Market by Country
6.3 Europe Online Providers Market by Country
Chapter 7. Europe Pruritus Therapeutics Market by Country
7.1 Germany Pruritus Therapeutics Market
7.1.1 Germany Pruritus Therapeutics Market by Disease Type
7.1.2 Germany Pruritus Therapeutics Market by Product
7.1.3 Germany Pruritus Therapeutics Market by Distribution Channel
7.2 UK Pruritus Therapeutics Market
7.2.1 UK Pruritus Therapeutics Market by Disease Type
7.2.2 UK Pruritus Therapeutics Market by Product
7.2.3 UK Pruritus Therapeutics Market by Distribution Channel
7.3 France Pruritus Therapeutics Market
7.3.1 France Pruritus Therapeutics Market by Disease Type
7.3.2 France Pruritus Therapeutics Market by Product
7.3.3 France Pruritus Therapeutics Market by Distribution Channel
7.4 Russia Pruritus Therapeutics Market
7.4.1 Russia Pruritus Therapeutics Market by Disease Type
7.4.2 Russia Pruritus Therapeutics Market by Product
7.4.3 Russia Pruritus Therapeutics Market by Distribution Channel
7.5 Spain Pruritus Therapeutics Market
7.5.1 Spain Pruritus Therapeutics Market by Disease Type
7.5.2 Spain Pruritus Therapeutics Market by Product
7.5.3 Spain Pruritus Therapeutics Market by Distribution Channel
7.6 Italy Pruritus Therapeutics Market
7.6.1 Italy Pruritus Therapeutics Market by Disease Type
7.6.2 Italy Pruritus Therapeutics Market by Product
7.6.3 Italy Pruritus Therapeutics Market by Distribution Channel
7.7 Rest of Europe Pruritus Therapeutics Market
7.7.1 Rest of Europe Pruritus Therapeutics Market by Disease Type
7.7.2 Rest of Europe Pruritus Therapeutics Market by Product
7.7.3 Rest of Europe Pruritus Therapeutics Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Bristol Myers Squibb Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals:
8.3.6 SWOT Analysis
8.4 Sanofi S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 SWOT Analysis
8.5 Astellas Pharma, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Cara Therapeutics, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.6.5 SWOT Analysis
8.7 GlaxoSmithKline PLC (GSK)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Teva Pharmaceutical Industries Ltd.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 SWOT Analysis
8.9 Amgen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. AbbVie, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Approvals & Trials:
8.10.6 SWOT Analysis
Unique Offerings 